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Abstract
Introduction The initial treatment for high-risk nonmuscle invasive bladder cancer (NMIBC) is endoscopic
resection of the tumour followed by BCG therapy. In
those who develop recurrence, the standard treatment is
radical cystectomy. Despite the advancement in surgical
technique and postoperative care, the degree of morbidity
associated with radical cystectomy remains high, therefore
less invasive treatment modalities are desirable. Therapies
targeting the programmed death (PD) pathway have shown
promise in urothelial carcinoma. We undertook the current
study to determine the safety and efficacy of administering
pembrolizumab (a monoclonal antibody targeting the
interaction between PD-1 and its ligand) in combination with
BCG in high-risk NMIBC.
Methods This is a single-centre phase I safety and
efficacy study of pembrolizumab used in combination with
intravesicular BCG treatment for subjects with pathologically
documented high-risk NMIBC despite having received two
courses of induction therapy or BCG treatment followed by
maintenance BCG. Fifteen subjects will be enrolled, patients
will receive treatment with 200 mg of pembrolizumab
every 21 days, starting 2 weeks from the initial endoscopic
resection and continuing for 6 weeks after the final dose
of BCG. The primary objective is to determine the safety of
administering pembrolizumab at a fixed dose of 200 mg
every 3 weeks in conjunction with intravesicular BCG
treatment in patients with high-risk NMIBC who have failed
previous treatment. Secondary objectives are to determine
the 19 weeks and the 3, 12 and 24 months post-treatment
completion complete response rate with combined
pembrolizumab and intravesicular BCG therapy in the
aforementioned patients.
Ethics and dissemination The study has been approved
by the Institutional Review Board of the Henry Ford Hospital.
The results of this study will be published in a peer-reviewed
journal and presented at a scientific conference.
Trial registration number NCT02324582.

Introduction
Bladder cancer is the fifth most common
cancer in the USA.1 The standard of care
for patients who have high-risk non-muscle

Strengths and limitations of this study
►► One of the first clinical trials to assess the safety and

efficacy of programmed death (PD)-1 inhibitors in
combination with BCG for patients with non-muscle
invasive high-risk urothelial carcinoma of the bladder after having failed two courses of BCG induction
therapy or BCG induction followed by maintenance
therapy.
►► Study provides extensive follow-up and multiple objective measures assessing the safety and efficacy
of PD-1 inhibitors.
►► This study is non-randomised and unblinded.
►► Long-term enrolment and frequent clinical obligations may result in failure of retention of subjects.

invasive bladder cancer (NMIBC) at presentation is a combination of endoscopic resection
and intravesicular BCG instillation. However,
only two-thirds of patients respond to BCG,
while the remaining one-third experience
recurrent disease, which is associated with a
poorer prognosis.2 3 Given that the only other
accepted treatment for recurrent high-risk
NMIBC is a radical cystectomy, a surgery associated with high morbidity, identification of
agents active against this disease process is
clearly warranted.4
The blockade of the immune checkpoint
pathway involving programmed death 1
(PD-1) receptor and its ligands, CD274
(PD-L1) and CD273 (PD-L2), has been
recently shown to be effective in the treatment
of various cancers including urothelial carcinoma (UC).5 6 Previous studies have identified that the expression of PD-L1 has been
linked to higher grade disease, and PD-L1
expression has been found to be extremely
abundant in BCG-induced bladder granulomata in patients failing BCG treatment.7 We
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Methods and analysis
Rationale
PD-1 is an inhibitory cell-surface receptor that can be
stimulated to be expressed on T cells, B cells, natural
killer (NK) T cells, monocytes and dendritic cells (DC).8
PD-L1 is widely expressed by haematopoietic, non-haematopoietic and tumour cells, whereas PD-L2 is expressed
mainly by DCs and macrophages.9 10 Higher expression
of PD-L1 in cancers is associated with poor survival as
tumours can evade the immune system by stimulating
PD-1.11 12 PD-L1 expression, a marker for response to
anti-PD-1 agents, is observed in 7% of pTa, 16% of pT1%
and 45% of carcinoma in situ (CIS) urothelial tumours.7
PD-L1 expression in these tumours is also associated
with high-grade disease. In addition, PD-L1 expression
is found to be extremely abundant in the BCG-induced
transitional epithelium granulomata in patients failing
BCG treatment.13 Recent pharmacokinetic (PK) studies
showing efficacy of anti-PD-1 agents in advanced bladder
cancer, advanced melanoma and other cancers support
combining these agents with BCG treatment in patients
with high-risk superficial bladder cancer to provide these
patients with an alternative to radical cystectomy if they
fail BCG alone. Previous experience with immunological
response supports dosing patients with anti-PD-1 agents
2–3 weeks before BCG treatment, which would allow the
bladder to be primed for BCG with the hopes of a greater
proportion of complete responses to BCG.13 In recent
years, pembrolizumab has been investigated, in conjunction with various other chemotherapeutic agents and
immunotherapy, in non-metastatic bladder cancer, metastatic bladder cancer and upper tract UC. Based on these
data and promising preliminary results, a combination of
pembrolizumab with BCG may be effective in preventing
recurrence of NMIBC after previously failed treatment.
Trial blinding
This is an open-label trial; therefore, the sponsor, investigator and subject will know the treatment administered.
Study design
This is a single-centre phase I safety and efficacy study
of pembrolizumab therapy used in combination with
bladder infused BCG treatment for subjects, 18 years or
2

Figure 1 Trial design for phase I study of pembrolizumab in
combination with Bacillus Calmette-Guérin for patients with
high risk non-muscle invasive bladder cancer. CIS, carcinoma
in situ; IFN, interferon.

older, with pathologically documented high-risk NMIBC
despite having received two courses of BCG induction
therapy or BCG induction followed by maintenance BCG.
Subjects will have confirmation of NMIBC. Approximately
20 subjects will be screened to treat 15 eligible subjects.
Subjects will be enrolled to a single treatment group of a
fixed dose of MK-3475 and BCG (figure 1).
Trial schedule
Trial schedule (figure 2) summarises the trial procedures
to be performed at each visit. It may be necessary to
perform these procedures at unscheduled time points if
deemed clinically necessary by the investigator. Furthermore, additional evaluations/testing may be deemed
Jamil ML, et al. BMJ Open 2019;9:e028287. doi:10.1136/bmjopen-2018-028287

BMJ Open: first published as 10.1136/bmjopen-2018-028287 on 17 July 2019. Downloaded from http://bmjopen.bmj.com/ on December 6, 2019 at Henry Ford Hospital. Protected by
copyright.

hypothesise that a combination of pembrolizumab, also
known as MK-3475, as it is labelled throughout the study
protocol, and BCG following endoscopic treatment of
high-risk NMIBC may be effective in improving outcomes
of NMIBC after endoscopic treatment in patients unfit or
unwilling to be treated with radical cystectomy. The aim
of this study is to determine the safety and response of
administering pembrolizumab (a monoclonal antibody
designed to block the interaction between PD-1 and its
ligand) in conjunction with BCG treatment in patients
with high-risk NMIBC. In this paper, we report the treatment protocol for the study.
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Figure 2 Trial schedule for phase I study of pembrolizumab in combination with Bacillus Calmette-Guérin for patients with
high risk non-muscle invasive bladder cancer. *Screening visit: No study required procedures should be conducted (unless
part of routine care) prior to the signing of the informed consent document. Screening visit laboratory procedures may be used
for day 1 of cycle 1 if completed within 10 days of day 1 of cycle 1. †Early discontinuation visit: all subjects who discontinue
treatment early for any reason should undergo all procedures listed in the flow chart for discontinuation visit. ‡If a subject has
completed all study treatment, the subject should complete the 30-day safety follow-up visit procedures listed in the flow
chart. §Follow-up visits should occur at approximately 3, 6, 9, 12, 18 and 24 months from week 19 cystoscopy. It is expected
that follow-up data will be collected from routine office visits, which generally occur every 3 months in this population. There
may be a shift in schedules if the participant has been given maintenance therapy or was found to have a recurrence. Subject
will complete a final set of questionnaires at the 3 month visit. Follow-up information may be collected via medical record
and document review only. However, patient contact via phone or in person may occur if information is not available via chart
review. **Subject identification card may be given at any time after consent process has occurred and prior to treatment on day
1 of cycle 1. ††Prior and concomitant medications will include any medications taken within the 28 days prior to consent and
through the safety visit and will include prescribed, over-the-counter and herbal/alternative remedies. ‡‡Poststudy treatment
anticancer therapy and recurrence status may be collected through follow-up chart review. §§Questionnaires: American Urologic
Association Symptoms Index, International prostate symptom score (IPSS) and Quality of Life will be completed prior to any
treatment or procedures scheduled for that visit. ***Transurethral resections: all TUBR will occur as part of SOC and as clinically
indicated. †††Adverse events will be collected from time of main study informed consent through 30 days post last study drug
infusion/treatment. ‡‡‡Physical exam: full physical exams are required at screening and at the 30-day follow-up. All other exams
may be symptom directed. §§§Performance status: Eastern cooperative group (ECOG) performance status scale should be used
to measure performance status. ****ECG, chest X-ray and pulmonary function tests will be completed prior to day 1 of cycle 1
and will only be repeated as clinically indicated. ††††Prothromin time (PT)/International normalization ratio (INR) and Acticatved
prothrombin time (aPTT) will be completed prior to all resections/possibly biopsies as standard of care. All other monitoring
of PT/INR and aPTT will only be completed as clinically indicated (ie, if on coumadin). ‡‡‡‡Cystoscopy will be performed as
standard of care but will be considered measures for efficacy. Biopsy will be performed as clinically indicated. §§§§Specimen
collection/correlative studies: whole blood, serum and urine will be collected at time of consent or may be collected at any time
prior to treatment on day 1 of cycle 1. Specimens for correlative study will also occur at each visit through week 19, repeat
cystoscopy (12 visits). Saliva will be collected only at baseline. Tumour tissue will only be collected at week 19 biopsy if a
biopsy is clinically indicated at the time of cystoscopy. Specimen collection is requested at 3, 6, 9, 12, 18 and 24 months followup visits if subject is being treated locally at the site, although not required. Tissue will only be collected if a biopsy is clinically
indicated at time of cystoscopy.
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necessary by the sponsor for reasons related to subject
safety. In some cases, such evaluation/testing may be
potentially sensitive in nature (eg, HIV, hepatitis C, etc),
and thus local regulations may require that additional
informed consent be obtained from the subject. In these
cases, such evaluations/testing will be performed in
accordance with those regulations.
Patient selection
Subjects, who meet required inclusion and exclusion
criteria are eligible for enrolment into the study (figure 3
and figure 4).
Trial treatment dosage, formulation, preparation and
frequency
BCG: the rationale for the use of the indicated dose of
BCG is based on Food and Drug Administration (FDA)-approved and commercially provided product. Dosing for
the intraluminal treatment of CIS and for the prophylaxis of recurrent papillary tumours consists of one phial
of BCG suspended in 50 mL preservative-free saline. The
4

preparation of the BCG suspension will be completed
using aseptic technique and according to FDA-approved
labelling and use information. Patients may have treatment with more than one phial to ensure treatment of
all tumour sites. BCG treatment will be administered
beginning on day 1 of cycle 3 (week 7) of pembrolizumab
after all procedures/assessments have been completed as
detailed on the trial flow chart. BCG treatment will be
repeated every 7 days at weeks 8, 9, 10, 11 and 12. BCG
treatment may be administered up to 1 day before or
after the scheduled date (at 7 days) due to administrative
reasons. All trial treatments will be administered on an
outpatient basis and according to institutional standards.
BCG dose modification has been shown to reduce efficacy; therefore, no dose modifications will be attempted
in this trial. The dose, frequency, route of administration
and duration are summarised in figure 5.
BCG treatment will be withheld for grade 2 haematuria, grade 1 fever and drug-related grade 4 haematological toxicities, and all other non-haematological toxicity
Jamil ML, et al. BMJ Open 2019;9:e028287. doi:10.1136/bmjopen-2018-028287
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Figure 3 Subject inclusion criteria for phase I study of pembrolizumab in combination with Bacillus Calmette-Guérin for
patients with high risk non-muscle invasive bladder cancer. CIS, carcinoma in situ.

Open access

grade ≥3 adverse effects (AEs) including laboratory
abnormalities and severe or life-threatening AEs. Treatment will be postponed until resolution of febrile illness,
urinary tract infection or gross haematuria and AE resolution to grade <1. In the event of a grade 1 or 2 immune-related adverse event requiring corticosteroid treatment,
BCG treatment may be delayed for up to 2 weeks with the
expectation that steroid treatment will be discontinued
prior to the next BCG treatment cycle. A delay of longer
than 2 weeks will permanently discontinue the patient
from BCG treatment within the study or permanent
withdrawal of the patient from the study. The choice will
be at the discretion of the treating investigator. Steroid
Jamil ML, et al. BMJ Open 2019;9:e028287. doi:10.1136/bmjopen-2018-028287

treatment for grade 3 or higher immune-mediated events
will require discontinuation of BCG treatment and/or
withdrawal from the study.
Pembrolizumab
A fixed dose of 100 mg pembrolizumab will be administered intravenously on day 1 of a 21-day cycle for up to
six cycles for the first three subjects. If one subject of
the initial three requires the dose of pembrolizumab to
be withheld or discontinued, the 100 mg cohort will be
expanded to six subjects. If two out of three or three out
of six subjects develop toxicity that requires the dose to be
withheld or discontinued, the dose will not be escalated
5
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Figure 4 Subject exclusion criteria for phase I study of pembrolizumab in combination with Bacillus Calmette-Guérin for
patients with high risk non-muscle invasive bladder cancer. *Chest X-ray, CT urogram or MRI and urogram are allowed to
ascertain the superficial nature of the disease when indicated, but not required. If urogram protocol is not available or contrast
allergy/poor renal function precludes such imaging, then non-contrast CT or MRI of the abdomen/pelvis within 90 days of study
entry will suffice. †Exceptions include upper urinary tract transitional cell cracinoma (TCC), basal cell carcinoma of the skin,
squamous cell carcinoma of the skin or in situ cervical cancer that has undergone potentially curative therapy. ‡Use of diseasemodifying agents, corticosteroids or immunosuppressive drugs. Replacement therapy (eg, thyroxine, insulin or physiologic
corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc) is not considered a form of systemic treatment. PD,
programmed death.

Open access

to 200 mg pembrolizumab every 3 weeks. All remaining
subjects will be treated at 100 mg pembrolizumab every
3 weeks for six cycles. This is based on multiple clinical
trials which have also used pembrolizumab at the aforementioned dose.14 An open-label phase I trial (PN001)
in subjects with melanoma was conducted to evaluate the
safety and clinical activity of single agent pembrolizumab.
The dose escalation portion of this trial evaluated three
dose levels, 1, 3 and 10 mg/kg, administered every 2 weeks
in subjects with advanced solid tumours. All three dose
levels were well tolerated, and no dose-limiting toxicities
were observed.14 This first-in-human study of pembrolizumab showed evidence of target engagement and objective evidence of tumour size reduction at all dose levels (1,
3 and 10 mg/kg every 2 weeks). No maximum tolerated
dose was identified.14 Selection of 200 mg as the appropriate dose for a switch to fixed dosing is based on simulation results indicating that 200 mg will provide exposures
that are reasonably consistent with those obtained with
2 mg/kg dose and importantly will maintain individual
patient exposures within the exposure range established in melanoma as associated with maximal clinical
response. A population PK model, which characterised
the influence of body weight and other patient covariates on exposure, has been developed using available
data from 476 subjects from PN001. The distribution of
exposures from the 200 mg fixed dose are predicted to
considerably overlap those obtained with the 2 mg/kg
dose, with some tendency for individual values to range
slightly higher with the 200 mg fixed dose. The slight
increase in PK variability predicted for the fixed dose relative to weight-based dosing is not expected to be clinically
important given that the range of individual exposures
is well contained within the range of exposures shown
in the melanoma studies of 2 and 10 mg/kg to provide
similar efficacy and safety.
Trial treatment will be administered on day 1 of
each cycle after all procedures/assessments have been
completed as detailed on the trial flow chart. Trial treatment may be administered up to 3 days before or after
the scheduled day 1 of each cycle due to administrative
reasons. Adverse events (both non-serious and serious)
associated with pembrolizumab exposure may represent
6

an immunological aetiology. These adverse events may
occur shortly after the first dose or several months after
the last dose of treatment. Pembrolizumab must be withheld for drug-related toxicities and severe or life-threatening AEs. Known and theoretical risks of pembrolizumab
are documented within the original study protocol and
management of said risks and AEs is also noted within the
original study protocol.
Objectives
Primary objective
To determine the safety of administering pembrolizumab
at a fixed dose of 200 mg every 3 weeks in conjunction
with intravesicular BCG treatment in patients with highrisk NMIBC who have failed two courses of induction
therapy or one course of BCG induction therapy followed
by maintenance therapy.
Secondary objective
To determine the 19 weeks and the 3, 12 and 24 months
post-treatment completion complete response rate
with combined pembrolizumab and intravesicular BCG
therapy for patients with non-muscle invasive superficial
bladder cancer who have failed two courses of induction
therapy or one course of BCG induction therapy followed
by maintenance therapy
Exploratory objectives
Three objectives are to examine pretreatment and
post-treatment (MK-3475/BCG) bladder biopsy specimens for PD-1, PD-L1 and CD3; to examine the whole
exome sequencing of subjects’ germline DNA and formalin-fixed paraffin-embedded tissue and to analyse blood
and urine specimens from enrollees for potential development of blood and urine assays for determination of
response to treatment.
Adverse effects
The investigator or qualified designee will assess each
subject to evaluate for potential new or worsening AEs
as specified in the detailed trial schedule and more
frequently, if clinically indicated. Adverse experiences will
be graded and recorded throughout the study and during
the follow-up period according to the National Cancer
Jamil ML, et al. BMJ Open 2019;9:e028287. doi:10.1136/bmjopen-2018-028287
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Figure 5 Trial treatment for phase I study of pembrolizumab in combination with Bacillus Calmette-Guérin for patients with
high risk non-muscle invasive bladder cancer. *The first three subjects will be dosed at 100 mg. If the Data Safety Review
Team approves, the dose will be escalated to 200 mg when the fourth subject is enrolled. †The MK-3475 dosing interval may
be increased due to toxicity. BCG treatment may be interrupted or delayed as per the instructions for use supplied with BCG.
‡
BCG: one phial of BCG suspended in 50 mL preservative-free saline.
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Statistical measures and analysis
This protocol aims at assessing the activity of one treatment arm, BCG in combination with pembrolizumab in
patients with NMIBC. We would like to detect an activity
which is at least 25% greater than that of historical
controls (50%) from case series of BCG-only treatment.
Sample size calculation for this protocol is based on the
work by Kahn et al.15 Using a one-stage design, 15 patients
will be enrolled in this study. Patient-related data will be
collected and transferred to an excel spreadsheet for
statistical analysis. SAS software V.9.4 will be used for all
data analysis. Descriptive statistics will be computed for
all study variables. Continuous variables will be described
with measures of central tendency (mean, median) and
dispersion (range, SD). Categorical variables will be
summarised as frequencies and percentages. Some examples include tumour stage (Ta, T1, CIS), age, Eastern
Jamil ML, et al. BMJ Open 2019;9:e028287. doi:10.1136/bmjopen-2018-028287

cooperative group (ECOG) performance status scale (0,
1, 2), sex and use of tobacco and alcohol.
For primary objective, the proportion of patients with
each AE will be reported along with the NCI CTCAE
grade of the AE (V.4.0). The Quality of Life Questionnaire, which includes one question with seven categorical responses, will be described with frequencies and
percentages. The American Urologic Association Symptoms Index Questionnaire, which includes seven questions each with a numerical score between 0 and 5 as well
as a final numerical sum of all responses, will be described
with measures of central tendency and dispersion. Due
to the questionnaires being given at three time points
(pretreatment, mid-treatment and post-treatment), the
responses may be analysed to look for longitudinal effects
over time for specific variables of interest with repeated
measures analysis of variance to evaluate changes and
control for individual differences (although this would
be very low power due to n=15).
For the secondary objective, subjects will be assessed at
19 weeks, 3, 12 and 24 months post-treatment completion for complete response. The outcome end point will
be complete response status at 19 weeks, 3, 12 and 24
months post-treatment to measure complete response,
recorded as yes or no and summarised as proportions and
a per cent.
For the exploratory objectives, Pearson’s or Spearman’s
rank correlation coefficient will be used to estimate
correlations between expression level change and treatment outcome, as well as the correlations between mutation presence and treatment outcome.
Patient and public involvement
Patient and the public were not involved in the design,
recruitment and conduction of the present study. Results
of the study will be disseminated to the study participants
on request. Patient advisors were not used in the conduction of this study.

Ethics, confidentiality and regulatory details
The investigator and sponsor of the study will adhere to all
applicable data privacy and confidentiality laws and regulations (ie, Health inurance portability and accountability
act (HIPAA)). Those applicable include institutional,
state and federal law. It is the responsibility of the investigator and sponsor to ensure the subject data as well as
sensitive study information is handled according to applicable guidelines and laws. Appropriate authorisation and
consent for use, disclosure or transfer of protected health
information must be obtained.
Subjects’ names will not be recorded on the case report
forms (CRF). Only the subject number and subject’s
initials will be recorded, where permitted. If the subject’s
name appears on any other document (eg, pathology
report), it must be obliterated on the copy of the document as appropriate. Study data stored on a computer
will be stored in accordance with local data protection
7
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Institute Common Terminology Criteria for Adverse
Events (NCI CTCAE) V.4.0. Toxicities will be characterised in terms of seriousness, causality, toxicity grading
and action taken with regard to trial treatment. AEs will
be recorded from the time the subject signs the consent
through 30 days post the last study treatment. All AEs of
unknown aetiology associated with pembrolizumab exposure should be evaluated to determine if it is possibly an
event of clinical interest of a potentially immunological
aetiology.
All known and theoretical risks and AEs of BCG and
pembrolizumab are documented within the original
study protocol for reference. Potential AEs and risks are
to be monitored for during each mandatory clinical visit.
All of the known and theoretical risks and AEs of BCG
and pembrolizumab are to be managed by the investigational team and all other necessary support staff. Management of the aforementioned risks and AEs is documented
within the original study protocol.
Parameters for determination of patient safety and for
trial suspension and discontinuation are noted within
the original study protocol. As per the original study
protocol, section 5.2.3.3 table 3, all grade 4 toxicities
result in permanent discontinuation from the study.
Further details and exceptions are noted within the original study protocol. As noted in section 5.8 of the original
study protocol, if there are any fatal treatment toxicities
or if one or more of the 15 subjects treated experience a
grade 4 toxicity, subject accrual will be suspended and all
data pertaining to the events will be reviewed by the Study
Investigators and Data Safety Review Team to determine
if there is the need for any corrective actions. Following
review and appropriate action by the investigating team,
subject accrual may recommence. If there is a second
fatal treatment/morbidity event related to the study treatment or procedures, the study will be terminated. If 4
of 15 subjects experience grade 4 toxicities, the accrual
will be suspended and reviewed for added appropriate
measures. If five subjects experience grade 4 toxicity, the
study will be terminated.
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Discussion
This open-label, single-centre, phase I treatment trial
intends to investigate the safety and efficacy of pembrolizumab in combination with intravesicular BCG. As previously mentioned, the optimal alternative to management
of patients unfit or unwilling to undergo radical cystectomy remains unknown. This prospective clinical trial
attempts to provide a more definitive treatment option
for NMIBC refractory to BCG. This study uses previously
established treatment modalities with available immunotherapeutic agents.
The design of the present study will allow the researchers
to discern the safety and efficacy of pembrolizumab and
BCG as a viable option for NMIBC. It has been well documented that although radical cystectomy provides definitive cancer control in NMIBC, the associated morbidity
and mortality continues to remain high.4 A non-surgical
option following BCG failure is desirable. Various studies
have demonstrated promising results in regard to the efficacy of agents such as pembrolizumab and it is presumed
that this trend will continue with increased investigation
and utilisation. It has been previously demonstrated that
the expression of PD-L1 is upregulated in mice models
following exposure to BCG, therefore lending to a theoretical synchronous relationship between the two agents
8

and providing further grounds for investigation into
this combination therapy.17–19 Several investigations
are currently underway assessing the potential benefits
of pembrolizumab. NCT02808143, a phase I clinical
trial, assessing the safety and efficacy of intravesicular
pembrolizumab and BCG, in a similar cohort of patients
as in the present study, is underway. Notably, the route
of administration between the two studies differs, as in
our investigation, pembrolizumab is administered intravenously, whereas in NCT02808143, pembrolizumab is
administered intravesically. However, despite these differences, it is essential that multiple studies at various institutions be performed to determine the optimal scheduling,
dose and route of administration, especially in the early
investigations of newer agents.
This potential benefit of pembrolizumab is being
assessed beyond patients limited to NMIBC. Of note,
pembrolizumab is being investigated in patients who
have developed metastatic urothelial cell carcinoma, in
combination with other agents or those with muscle-invasive disease.20 A phase III randomised clinical trial,
currently being carried out by Fradet et al, NCT02256436,
is seeking to determine the potential benefit of receiving
pembrolizumab versus paclitaxel, docetaxel or vinflunine
in patients who have metastatic, locally advanced or unresectable urothelial cell carcinoma following recurrence
or progression after treatment with platinum-containing
chemotherapy. Recent findings from the aforementioned
investigation have demonstrated a significant increase in
overall survival in those treated with pembrolizumab. It
was also noted that the rate of treatment-related AEs was
lower in those who received pembrolizumab, 62.0% than
those who received chemotherapy, 90.6%.20 21 Other investigations, such as NCT02621151, are currently assessing
the combination of concurrent pembrolizumab, chemotherapy and radiation therapy in patients with muscle
invasive bladder cancer who are also not deemed surgical
candidates. The potential vast utility of pembrolizumab is
encouraging.
Ultimately, if the combination of pembrolizumab and
BCG is to yield promising results, it would provide patients
with an alternative to radical cystectomy and potentially
change the standard of care.
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laws. The subjects will be informed that representatives
of the sponsor or its designee, institutional review board
and regulatory authorities may inspect their medical
records to verify the information collected, and that all
personal information made available for inspection will
be handled in strictest confidence and in accordance with
local data protection laws.
Qualified staff of the sponsor will monitor the study
according to a pre-arranged monitoring plan. Monitoring
of the study will include:
►► Evaluation of study progress.
►► Verification of CRF accuracy and completeness.
►► Resolution of inconsistencies in study records.
►► Assurance of protocol requirements and investigator’s
obligations are fulfilled.
►► Assurance of compliance with applicable laws and
regulations.
Study monitors will periodically review all CRFs and
supporting source documentation of participating
subjects. The CRFs and supporting documentation must
remain up to date and available to the study monitor
as arranged. CRF data entry will be verified to correspond with source documentation (laboratory, imaging,
pathology reports, etc) and reviewed for completeness.
Data discrepancies will be identified and reported to the
investigator and site staff.
Protocol deviations will be identified and recorded on
a deviation log.
This submission was drafted under the use of the Standard Protocol Items: Recommendations for Interventional Trials reporting guidelines.16

Open access
1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA
Cancer J Clin 2003;53:5–26.
2. Herr HW, Badalament RA, Amato DA, et al. Superficial bladder
cancer treated with bacillus Calmette-Guerin: a multivariate analysis
of factors affecting tumor progression. J Urol 1989;141:22–8.
3. Hudson MA, Herr HW. Carcinoma in situ of the bladder. J Urol
1995;153(3 Pt 1):564–72.
4. Lavallée LT, Schramm D, Witiuk K, et al. Peri-operative morbidity
associated with radical cystectomy in a multicenter database of
community and academic hospitals. PLoS One 2014;9:e111281.
5. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of antiPD-L1 antibody in patients with advanced cancer. N Engl J Med
2012;366:2455–65.
6. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and
immune correlates of anti-PD-1 antibody in cancer. N Engl J Med
2012;366:2443–54.
7. Inman BA, Sebo TJ, Frigola X, et al. PD-L1 (B7-H1) expression
by urothelial carcinoma of the bladder and BCG-induced
granulomata: associations with localized stage progression. Cancer
2007;109:1499–505.
8. Vegt PD, Witjes JA, Witjes WP, et al. A randomized study of
intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus
Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and
carcinoma in situ of the bladder. J Urol 1995;153(3 Pt 2):929–33.
9. Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in
tolerance and immunity. Annu Rev Immunol 2008;26:677–704.
10. Zhang P, Su DM, Liang M, et al. Chemopreventive agents induce
programmed death-1-ligand 1 (PD-L1) surface expression in breast
cancer cells and promote PD-L1-mediated T cell apoptosis. Mol
Immunol 2008;45:1470–6.
11. Konishi J, Yamazaki K, Azuma M, et al. B7-H1 expression on
non-small cell lung cancer cells and its relationship with tumorinfiltrating lymphocytes and their PD-1 expression. Clin Cancer Res
2004;10:5094–100.

Jamil ML, et al. BMJ Open 2019;9:e028287. doi:10.1136/bmjopen-2018-028287

12. Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory B7-H1
in renal cell carcinoma patients: Indicator of tumor aggressiveness
and potential therapeutic target. Proc Natl Acad Sci U S A
2004;101:17174–9.
13. De Libero G, Mori L. The T-cell response to lipid antigens of
mycobacterium tuberculosis. Front Immunol 2014;5:219.
14. Skinner EC, Goldman B, Sakr WA, et al. SWOG S0353: Phase II
trial of intravesical gemcitabine in patients with nonmuscle invasive
bladder cancer and recurrence after 2 prior courses of intravesical
bacillus Calmette-Guérin. J Urol 2013;190:1200–4.
15. Khan I, Sarker SJ, Hackshaw A. Smaller sample sizes for phase
II trials based on exact tests with actual error rates by tradingoff their nominal levels of significance and power. Br J Cancer
2012;107:1801–9.
16. Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement:
defining standard protocol items for clinical trials. Ann Intern Med
2013;158:200–7.
17. Chevalier MF, Schneider AK, Cesson V, et al. Conventional and PDL1-expressing Regulatory T Cells are Enriched During BCG Therapy
and may Limit its Efficacy. Eur Urol 2018;74:540–4.
18. Hashizume A, Umemoto S, Yokose T, et al. Enhanced expression of
PD-L1 in non-muscle-invasive bladder cancer after treatment with
Bacillus Calmette-Guerin. Oncotarget 2018;9:34066–78.
19. Wang Y, Liu J, Yang X, et al. Bacillus Calmette-Guérin and anti-PD-L1
combination therapy boosts immune response against bladder
cancer. Onco Targets Ther 2018;11:2891–9.
20. Bellmunt J, Powles T, Vogelzang NJ. A review on the evolution of
PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.
Cancer Treat Rev 2017;54:58–67.
21. Fradet Y, Bellmunt J, De Wit R, et al. Pembrolizumab (pembro) versus
investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent,
advanced urothelial cancer (UC): 2-year follow-up from the phase
3 KEYNOTE-045 trial. Journal of Clinical Oncology 2018;36(15_
suppl):4521.

9

BMJ Open: first published as 10.1136/bmjopen-2018-028287 on 17 July 2019. Downloaded from http://bmjopen.bmj.com/ on December 6, 2019 at Henry Ford Hospital. Protected by
copyright.

References

